Telix Pharmaceuticals Ltd Share Price Today: Live Updates & Key Insights
Telix Pharmaceuticals Ltd share price today is $8.76, up 2.1%. The stock opened at $8.78 against the previous close of $8.57, with an intraday high of $8.93 and low of $8.72.
Telix Pharmaceuticals Ltd Share Price Chart
Telix Pharmaceuticals Ltd
Telix Pharmaceuticals Ltd Share Price Performance
Telix Pharmaceuticals Ltd Institutional Holdings
Telix Pharmaceuticals Ltd Market Status
Telix Pharmaceuticals Ltd Fundamentals
Market Cap 3277.22 M
PB Ratio 6.9896
PE Ratio 475.5
Enterprise Value 3280.26 M
Total Assets 1770.91 M
Volume 374130
Telix Pharmaceuticals Ltd Company Financials
About Telix Pharmaceuticals Ltd & investment objective
Company Information Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Organisation Biotechnology
Employees 1120
Industry Biotechnology
CEO Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., Ph.D
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:
Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*
Take your next step
Telix Pharmaceuticals Ltd FAQs
What is the share price of Telix Pharmaceuticals Ltd today?
The current share price of Telix Pharmaceuticals Ltd is $8.76.
Can I buy Telix Pharmaceuticals Ltd shares in India?
Yes, Indian investors can buy Telix Pharmaceuticals Ltd shares by opening an international trading and demat account with Motilal Oswal.
How to buy Telix Pharmaceuticals Ltd shares in India?
You can easily invest in Telix Pharmaceuticals Ltd shares from India by:
- Direct Investment:
Opening an international trading account with Motilal Oswal which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy Telix Pharmaceuticals Ltd shares. - Indirect Investment:
Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of Telix Pharmaceuticals Ltd.
Can I buy fractional shares of Telix Pharmaceuticals Ltd?
Yes, many platforms allow you to buy fractional shares starting from as low as $1.
What is the market capitalization value of Telix Pharmaceuticals Ltd?
Telix Pharmaceuticals Ltd has a market cap of $3277.22 M.
In which sector does Telix Pharmaceuticals Ltd belong?
Telix Pharmaceuticals Ltd operates in the Biotechnology sector.
What documents are required to invest in Telix Pharmaceuticals Ltd stocks?
To invest, you typically need:
What is the PE and PB ratio of Telix Pharmaceuticals Ltd?
The PE ratio of Telix Pharmaceuticals Ltd is 475.50 and the PB ratio is 6.99.